Logo-bi
Bioimpacts. 2019;9(4): 199-209. doi: 10.15171/bi.2019.25
PMID: 31799156        PMCID: PMC6879708

Original Research

Design, synthesis and evaluation of biological activities of some novel anti-TB agents with bio-reducible functional group

Hossein Khani-Meinagh 1, Hossein Mostafavi 1 * ORCID, Norbert Reiling 2,3, Majid Mahdavi 4, Gholamreza Zarrini 4

Cited by CrossRef: 2


1- Rostampour S, Eslami F, Babaei E, Mostafavi H, Mahdavi M. An Active Compound from the Pyrazine Family Induces Apoptosis by Targeting the Bax/Bcl2 and Survivin Expression in Chronic Myeloid Leukemia K562 Cells. ACAMC. 2024;24(3):203 [Crossref]
2- Alizadeh S, Akhlaghi S, Mostoufi A, Nosratyan A, Fereidoonnezhad M. Exploring Anticancer Potential: Synthesis and Assessment of the Biological Activity of Novel Synthesized Pyrazinoic Acid Derivatives. ChemistrySelect. 2024;9(19) [Crossref]
3- El-Shoukrofy M, Atta A, Fahmy S, Sriram D, Shehat M, Labouta I, Mahran M. Challenging the Biginelli scaffold to surpass the first line antitubercular drugs: Mycobacterium tuberculosis thymidine monophosphate kinase (TMPK mt ) inhibition activity and molecular modelling studies . Journal of Enzyme Inhibition and Medicinal Chemistry. 2024;39(1) [Crossref]
4- Dhameliya T, Bhakhar K, Gajjar N, Patel K, Devani A, Hirani R. Recent advancements and developments in search of anti-tuberculosis agents: A quinquennial update and future directions. Journal of Molecular Structure. 2022;1248:131473 [Crossref]
5- Akhlaghi S, Mostoufi A, Kalantar H, Fereidoonnezhad M. Synthesis and biological evaluations of novel pyrazinoic acid derivatives as anticancer agents. Med Chem Res. 2022;31(4):580 [Crossref]


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge